News >

Expert Reflects on Recent Pivotal Data in RCC

Angelica Welch
Published: Monday, Dec 17, 2018

Daniel J. George, MD

Daniel J. George, MD
Renal cell carcinoma (RCC) is a field that is shifting dramatically in the metastatic setting, but progress has been slower for patients with high-risk stage III disease, said Daniel J. George, MD.

on Genitourinary Cancers, George, professor of Medicine and Surgery, member, Duke Cancer Institute, discussed the status of treatment for patients with high-risk stage III RCC, as well as the role of sunitinib (Sutent) and checkpoint inhibitors in the RCC paradigm.

OncLive®: What are the recent data seen with TKIs in the landscape?

George: RCC is a field that is dramatically changing—we are making progress in advanced metastatic disease. However, for patients with stage III disease who are high risk for disease recurrence after surgery, there really have not been any breakthroughs until recently. For the most part, that has been an unmet need. We have done some clinical trials looking at TKIs in that setting. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication